Press release
Triptorelin Market to surpass US$ 670 million by 2026
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1963
Triptorelin is agonist analogue of natural gonadotropin-releasing hormone (GnRH). Triptorelin act as GnRH agonists, by reducing the level of sex hormones such as testosterone in the body. Reducing testosterone levels helps to slow progression of prostate cancer in addition to reducing the bone pain, urinary problems and other symptoms of prostate cancer.
Moreover, key players in the triptorelin market are engaged in various activities to expand their geographical presence. For instance, in December 2015, United Laboratories Inc. and Debiopharm International SA made and exclusive agreement for the distribution and commercialization of Pamorelin: 1, 3, and 6-month formulations in the Philippines, for the treatment of locally advanced and metastatic hormone-dependent prostate cancer and as adjuvant to radiotherapy in high-risk localized and locally advanced prostate cancer, and for the treatment of endometriosis (1- and 3-month formulations only).
Browse 26 Market Data Tables and 21 Figures spread through 152 Pages and in-depth TOC on "Triptorelin Market, by Product Type (Triptorelin pamoate, Triptorelin acetate, and Triptorelin embonate), by Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer and Central Precocious Puberty), By End User (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) - Global Forecast to 2026"
Furthermore, key players are engaged in launching triptorelin-based product in market along with gaining regulatory approval for the same. Debiopharm Group are continuously launching triptorelin product portfolio in various geographical locations.
For instance, in September 2014, Actavis Specialty Pharmaceuticals Co. (operated as a subsidiary of Teva Pharmaceutical Industries Ltd.) and Debiopharm Group announced launch of Trelstar (triptorelin pamoate) in six-month dosing option (22.5 mg) in Canada. Trelstar is indicated for the palliative treatment of hormone dependent advanced prostate cancer in Canada. Moreover, new dosing option eases the burden of patients, with decreased number of injections and thereby low incidence of injection site pain, while providing long-term sustained testosterone suppression.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1963
Key takeaways of the Triptorelin Market:
The global triptorelin market is expected to expand at a CAGR of 5.2% during the forecast period (2018 – 2026), owing to high prevalence of prostate cancer patients, worldwide. For instance, according to International Agency for Research on Cancer, 2012 data findings, prostate cancer accounted for 307,000 deaths in 2012, making it fifth leading cause of death from cancer in men globally.
Among product type, triptorelin pamoate segment accounted for higher revenue share in 2017, owing to its wide application and higher acceptability by key manufacturers in prostate cancer medication.
Some of the major players operating in global triptorelin market include Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
1001 4th Ave,, #3200, Seattle, WA 98154
#3200
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Triptorelin Market to surpass US$ 670 million by 2026 here
News-ID: 1167197 • Views: …
More Releases from CMI Research
Complete guide to Eosinophilic Esophagitis Market 2023: Expanding due to immune …
Eosinophilic Esophagitis (EoE) is a chronic inflammatory condition of the esophagus. It is characterized by the accumulation of a type of white blood cells called eosinophils in the lining of the esophagus. EoE can cause a range of symptoms, including difficulty swallowing, food impaction, chest pain, and heartburn.
Steroids are the primary treatment option for EoE. They help control inflammation and reduce the number of eosinophils in the esophagus. Topical steroids…
A complete guide to Adoptive Cell Therapy Market 2023: growing demand for person …
Adoptive cell therapy (ACT) is a form of immunotherapy that involves the genetic modification of T cells to enhance their cancer-fighting capabilities. This treatment has shown promising results in the treatment of several types of cancer and is expected to become a major player in the oncology market in the coming years.
The global adoptive cell therapy market size was valued at USD 1.12 billion in 2021 and is projected to…
A complete guide to the TCV Vaccines Market 2023: market size, growth trends, ke …
Conjugate vaccine (Vi-TT) consists of Vi antigen that is coupled to a carrier protein. In this vaccine, polysaccharide is attached to a more complex protein. In infants, these cells can effectively develop immune protection against pathogens. Polysaccharides are weaker by itself, however, by binding to a protein carrier, polysaccharides can enter into important parts of the immune system with ease and can get more easily noticed by the immunity system…
A complete guide to Corporate Wellness Market 2023: Market size, growth trends, …
The corporate wellness market has been gaining popularity over the years as more companies recognize the importance of keeping their employees healthy and productive. Corporate wellness programs are designed to improve the overall health and well-being of employees by providing them with resources and support to manage their physical and mental health.
The corporate wellness market is expected to grow significantly from 2023-2030. According to a report by Coherent Market Insights,…
More Releases for Triptorelin
Triptorelin Market Size, Share, Trends, and Forecast: 2024-2031
"Triptorelin Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Triptorelin market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Triptorelin industry, providing stakeholders with a nuanced perspective on market dynamics.
Furthermore, the report…
Triptorelin Market, by Product Type (Triptorelin pamoate, Triptorelin acetate, a …
The triptorelin market was valued at US$ 171.7 Mn in 2022 and is expected to exhibit a CAGR of 5.5% over the forecast period (2023-2033).
Among the numerous medications for achieving medical castration, gonadotropin-releasing hormone (GnRH) agonists have a better safety and effectiveness profile than oestrogens and anti-androgens. Slow-release GnRH agonist formulations also give patients flexibility, raise quality of life, and eventually lower costs. Prostate cancer typically advances with rising testosterone…
Global Triptorelin Acetate Market Production and Consumption Reports 2018
This report studies the global Triptorelin Acetate market status and forecast, categorizes the global Triptorelin Acetate market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
Triptorelin Acetate is a peptide formulation for injection that was initially developed and continues to be used mainly in the treatment of advanced metastatic…
Triptorelin Market Trends, and Forecast to 2026
Gonadotropin-releasing hormone (GnRH) agonists have greater safety and efficacy profile than estrogens and anti-androgens among various therapies of achieving medical castration. Furthermore, slow-release formulations of GnRH agonists offer patients flexibility, improves quality of life, and eventually reduce cost. Most of the times, prostate cancer progresses with increasing testosterone hormone. Moreover, the production of testosterone can be stopped by surgically removing the testicles or thorough medication therapy. Triptorelin is GnRH agonists…
Triptorelin Market to surpass US$ 670 million by 2026
Gonadotropin-releasing hormone (GnRH) agonists have greater safety and efficacy profile than estrogens and anti-androgens among various therapies of achieving medical castration. Furthermore, slow-release formulations of GnRH agonists offer patients flexibility, improves quality of life, and eventually reduce cost. Most of the times, prostate cancer progresses with increasing testosterone hormone. Moreover, the production of testosterone can be stopped by surgically removing the testicles or thorough medication therapy. Triptorelin is GnRH agonists…
Global Triptorelin Acetate Market 2021- Analysis and Trends
“Global Triptorelin Acetate Market by Manufacturers, Regions, Type and Application, Forecast to 2021” Purchase This Report by calling ResearchnReports.com at +1-888-631-6977.
The Global Triptorelin Acetate Market 2016 Research Report is a professional in-depth study report and indeed a valuable source of guidance and direction for companies and individuals interested in the market.
There has been an increasing demand for Global Triptorelin Acetate Market, so several market analysts have dedicated time and…
